Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
MISSISSAUGA, ON, May 13, 2022 Ahead of Canada Innovation Week, Roche, one of the world's leading pharmaceutical, in vitro diagnostics, and healthcare technology companies celebrates 125 years of...
In Canada, lung cancer is the most commonly diagnosed cancer, with estimates that 29,600 Canadians received a diagnosis in 20211 Tecentriq® (atezolizumab) is the first and only cancer immunotherapy...
MISSISSAUGA, ON, Feb. 3, 2022 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...
The CADTH recommendation is a step in the right direction for the public reimbursement of Evrysdi; however, limits access to treatment for many patients with SMA Canadians now wait more than 450 days ...
BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate cost-effective access to targeted treatments for cancer patients...
SMA is a progressive neuromuscular condition that affects the nerve cells in the spinal cord and impacts the muscles used for activities such as breathing, eating, crawling and walking i ii EVRYSDI®...
MISSISSAUGA, ON, March 18, 2021 /CNW/ - The Roche Canada Artificial Intelligence Centre of Excellence (AI CoE) is excited to collaborate with Answer ALS and EverythingALS to launch an initiative...
New approval provides Canadian patients with HER2-positive early breast cancer a proven treatment regimen in a neo adjuvant setting where meaningful reductions in tumour size can have long-term...
First-in-class antibody-drug conjugate that specifically targets CD79b and destroys B cells through the delivery of an anti-cancer agent ii,iii MISSISSAUGA, ON, Sept. 24, 2020 /CNW/ - Hoffmann-La...
ENSPRYNG is a targeted IL-6R treatment that is administered every four weeks by subcutaneous injection[1] MISSISSAUGA, ON, Aug. 31, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced...
Program will fund 11 unique solutions for challenges posed by COVID-19 from Canadians across the country MISSISSAUGA, ON, June 2, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to...
Data show more than half of trial patients across all 10 tumour types studied had responses to treatment,2 including in patients where cancer has spread to the central nervous system3 MISSISSAUGA,...
Coalition created a publicly available centralized repository to enhance research MISSISSAUGA, ON, April 16, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce the launch of ...
Coalition created a publicly available centralized repository to enhance research MISSISSAUGA, ON, April 8, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce the launch of...
All Canadians invited to develop solutions for challenges posed by COVID-19 MISSISSAUGA, ON, March 31, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce the launch of the...
Burden of Idiopathic Pulmonary Fibrosis in Canada report sheds light on barriers to treatment and resources for Canadians living with this debilitating condition MISSISSAUGA, ON, Nov. 20, 2019 /CNW/...
Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung cancer live longer, with a 30% reduction in the risk of death2 MISSISSAUGA, ON,...
Hemlibra is the only treatment that can be self-injected subcutaneously once weekly for patients with hemophilia A without factor VIII inhibitors1 MISSISSAUGA, ON, June 18, 2019 /CNW/ - Hoffmann-La...
MISSISSAUGA, ON, March 19, 2019 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter...
SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche Limited...
HEMLIBRA is the first new treatment in almost 20 years for this most severe form of hemophilia1 and the only medicine that is self-injected once weekly MISSISSAUGA, ON, Aug. 7, 2018 /CNW/ -...
GAZYVA is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma.1 MISSISSAUGA, ON, July 9, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today...
OCREVUS is a new treatment for a rare and worsening form of MS that impacts 10-15 per cent of Canadians living with the disease1 MISSISSAUGA, ON, Feb. 15, 2018 /CNW/ - Hoffmann-La Roche Limited...
ACTEMRA® is the first non-steroid treatment designed to directly target the interleukin-6 (IL-6) receptor, offering a new option to treat GCA1 MISSISSAUGA, ON, Nov. 2, 2017 /CNW/ - Hoffmann-La Roche...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.